Cargando…

Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study

OBJECTIVE: Contribution of individual and combined inflammatory markers in prognosis after stroke was still undefined. We aimed to investigate the association of systemic and local vascular inflammatory markers and recurrent stroke as well as impact on poor functional outcome. METHODS: In this pre-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiejie, Lin, Jinxi, Pan, Yuesong, Wang, Mengxing, Meng, Xia, Li, Hao, Wang, Yilong, Zhao, Xingquan, Qin, Haiqiang, Liu, Liping, Wang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235241/
https://www.ncbi.nlm.nih.gov/pubmed/35761288
http://dx.doi.org/10.1186/s12974-022-02467-1
_version_ 1784736271969550336
author Li, Jiejie
Lin, Jinxi
Pan, Yuesong
Wang, Mengxing
Meng, Xia
Li, Hao
Wang, Yilong
Zhao, Xingquan
Qin, Haiqiang
Liu, Liping
Wang, Yongjun
author_facet Li, Jiejie
Lin, Jinxi
Pan, Yuesong
Wang, Mengxing
Meng, Xia
Li, Hao
Wang, Yilong
Zhao, Xingquan
Qin, Haiqiang
Liu, Liping
Wang, Yongjun
author_sort Li, Jiejie
collection PubMed
description OBJECTIVE: Contribution of individual and combined inflammatory markers in prognosis after stroke was still undefined. We aimed to investigate the association of systemic and local vascular inflammatory markers and recurrent stroke as well as impact on poor functional outcome. METHODS: In this pre-specified substudy of the Third China National Stroke Registry (CNSR-III), 10,472 consecutive acute ischemic stroke or TIA patients with available centralized-measured levels of Interleukin-6 (IL-6), high sensitive C-reactive protein (hsCRP), IL-1 receptor antagonist (IL-1Ra), lipoprotein-associated phospholipase A(2) mass (Lp-PLA(2)) and activity (Lp-PLA(2)-A), and YKL-40 from 171 sites were enrolled. The primary outcomes consisted of stroke recurrence and poor functional outcome defined as modified Rankin Scale (mRS) score of 2–6 within 1 year. RESULTS: There were 1026 (9.8%) and 2395 (23.4%) patients with recurrent stroke and poor functional outcome within 1 year. The highest quartiles of IL-6 (adjusted HR, 1.36; 95% CI 1.13–1.64; P = 0.001), hsCRP (adjusted HR, 1.41; 95% CI 1.17–1.69; P = 0.0003) and YKL-40 (adjusted HR, 1.28; 95% CI 1.06–1.56; P = 0.01) were associated with increased risk of recurrent stroke; and the highest quartiles of IL-6 (adjusted OR 1.93; 95% CI 1.64–2.27; P < 0.0001), IL-1Ra (adjusted OR 1.60; 95% CI 1.37–1.87; P < 0.0001), hsCRP (adjusted OR 1.60; 95% CI 1.37–1.86; P < 0.0001) and YKL-40 (adjusted OR 1.21; 95% CI 1.03–1.42; P = 0.02) were correlated with increased risk of poor functional outcome. In the multivariate stepwise regression analysis including all markers with backward selection, elevated levels of IL-6 or YKL-40 were associated with recurrent stroke (IL6: OR, 1.34; 95% CI 1.19–1.52; P < 0.0001; YKL-40: OR, 1.01; 95% CI 1.01–1.03; P = 0.004) and poor functional outcome (IL6: OR, 1.68; 95% CI 1.46–1.93; P < 0.0001; YKL-40: OR, 1.02; 95% CI 1.01–1.03; P = 0.0001). Adding IL-6 and YKL-40 significantly increased the area under the receiver operating characteristic curves for the prediction models of Essen Stroke Risk Score (0.03, P < 0.0001) and Totaled Health Risks in Vascular Events Score (0.07, P < 0.0001), and yielded continuous net reclassification improvement (19.0%, P < 0.0001; 33.0, P < 0.0001). CONCLUSIONS: In the patients with ischemic stroke or TIA, IL-6 and YKL-40 were independently associated with recurrent stroke and poor functional outcome, and improved risk classification of clinical risk algorithms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02467-1.
format Online
Article
Text
id pubmed-9235241
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92352412022-06-28 Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study Li, Jiejie Lin, Jinxi Pan, Yuesong Wang, Mengxing Meng, Xia Li, Hao Wang, Yilong Zhao, Xingquan Qin, Haiqiang Liu, Liping Wang, Yongjun J Neuroinflammation Research OBJECTIVE: Contribution of individual and combined inflammatory markers in prognosis after stroke was still undefined. We aimed to investigate the association of systemic and local vascular inflammatory markers and recurrent stroke as well as impact on poor functional outcome. METHODS: In this pre-specified substudy of the Third China National Stroke Registry (CNSR-III), 10,472 consecutive acute ischemic stroke or TIA patients with available centralized-measured levels of Interleukin-6 (IL-6), high sensitive C-reactive protein (hsCRP), IL-1 receptor antagonist (IL-1Ra), lipoprotein-associated phospholipase A(2) mass (Lp-PLA(2)) and activity (Lp-PLA(2)-A), and YKL-40 from 171 sites were enrolled. The primary outcomes consisted of stroke recurrence and poor functional outcome defined as modified Rankin Scale (mRS) score of 2–6 within 1 year. RESULTS: There were 1026 (9.8%) and 2395 (23.4%) patients with recurrent stroke and poor functional outcome within 1 year. The highest quartiles of IL-6 (adjusted HR, 1.36; 95% CI 1.13–1.64; P = 0.001), hsCRP (adjusted HR, 1.41; 95% CI 1.17–1.69; P = 0.0003) and YKL-40 (adjusted HR, 1.28; 95% CI 1.06–1.56; P = 0.01) were associated with increased risk of recurrent stroke; and the highest quartiles of IL-6 (adjusted OR 1.93; 95% CI 1.64–2.27; P < 0.0001), IL-1Ra (adjusted OR 1.60; 95% CI 1.37–1.87; P < 0.0001), hsCRP (adjusted OR 1.60; 95% CI 1.37–1.86; P < 0.0001) and YKL-40 (adjusted OR 1.21; 95% CI 1.03–1.42; P = 0.02) were correlated with increased risk of poor functional outcome. In the multivariate stepwise regression analysis including all markers with backward selection, elevated levels of IL-6 or YKL-40 were associated with recurrent stroke (IL6: OR, 1.34; 95% CI 1.19–1.52; P < 0.0001; YKL-40: OR, 1.01; 95% CI 1.01–1.03; P = 0.004) and poor functional outcome (IL6: OR, 1.68; 95% CI 1.46–1.93; P < 0.0001; YKL-40: OR, 1.02; 95% CI 1.01–1.03; P = 0.0001). Adding IL-6 and YKL-40 significantly increased the area under the receiver operating characteristic curves for the prediction models of Essen Stroke Risk Score (0.03, P < 0.0001) and Totaled Health Risks in Vascular Events Score (0.07, P < 0.0001), and yielded continuous net reclassification improvement (19.0%, P < 0.0001; 33.0, P < 0.0001). CONCLUSIONS: In the patients with ischemic stroke or TIA, IL-6 and YKL-40 were independently associated with recurrent stroke and poor functional outcome, and improved risk classification of clinical risk algorithms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02467-1. BioMed Central 2022-06-06 /pmc/articles/PMC9235241/ /pubmed/35761288 http://dx.doi.org/10.1186/s12974-022-02467-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Jiejie
Lin, Jinxi
Pan, Yuesong
Wang, Mengxing
Meng, Xia
Li, Hao
Wang, Yilong
Zhao, Xingquan
Qin, Haiqiang
Liu, Liping
Wang, Yongjun
Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study
title Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study
title_full Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study
title_fullStr Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study
title_full_unstemmed Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study
title_short Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study
title_sort interleukin-6 and ykl-40 predicted recurrent stroke after ischemic stroke or tia: analysis of 6 inflammation biomarkers in a prospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235241/
https://www.ncbi.nlm.nih.gov/pubmed/35761288
http://dx.doi.org/10.1186/s12974-022-02467-1
work_keys_str_mv AT lijiejie interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT linjinxi interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT panyuesong interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT wangmengxing interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT mengxia interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT lihao interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT wangyilong interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT zhaoxingquan interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT qinhaiqiang interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT liuliping interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT wangyongjun interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy
AT interleukin6andykl40predictedrecurrentstrokeafterischemicstrokeortiaanalysisof6inflammationbiomarkersinaprospectivecohortstudy